Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.00.

Several analysts have weighed in on CNTX shares. JonesTrading started coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen cut shares of Context Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd.

Context Therapeutics Stock Performance

Shares of Context Therapeutics stock opened at $2.90 on Tuesday. The firm has a 50-day moving average of $2.08 and a 200-day moving average of $1.43. The stock has a market cap of $266.45 million, a PE ratio of -12.08 and a beta of 1.97. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.30.

Hedge Funds Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp lifted its position in shares of Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after acquiring an additional 13,000 shares during the period. Blue Owl Capital Holdings LP increased its position in shares of Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after purchasing an additional 25,000 shares during the period. Virtu Financial LLC acquired a new position in Context Therapeutics in the fourth quarter valued at about $43,000. Clear Harbor Asset Management LLC raised its stake in Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after purchasing an additional 35,000 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Context Therapeutics during the fourth quarter worth about $68,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.